2016年9月18日星期日

Azelnidipine



Azelnidipine (INN; marketed under the brand name CalBlock — カルブロック) is a dihydropyridine calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate.

Product Description

Product Name : Azelnidipine
Chemical Name: 2-Amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-[1-(diphenyl)-3-azetidyl]
CAS.NO: 123524-52-7
Molecular Structure
Molecular Formula: C33H34N4O6
Molecular Weight: 582.65
Physical and Chemical Properties :Appearance: Pale yellow to white crystalline powder.
Criteria: level superscript
Melting point :122-126°C
Content: ≥ 99.0%
Heating reduction: ≤ 0.1%
Burning residue: ≤ 0.2%Applications:Used in the treatment of bronchial asthma, bronchiectasis, chronic bronchitis, pulmonary tuberculosis, pneumoconiosis, chronic respiratory diseases such as emphysema.
Package:25kg fiber drum or according to customer requirements for packaging 
Specifications:
Spec.:99% of Azelnidipine Powder
Analysis Test

Specification

Result

Description

white crystalline powder,odorless

Conforms

Solubility

Easily soluble in water, unsoluble in ethanol

Conforms
PH6.0~7.56.9

Solution clarity and color

solution should be clear and colorless

Conforms

Related substances
5’CMP 0.3%
Simple impurity
Total other impurity
0.01%
0.03%
0.10%

Chloride
0.05%

Conforms

Ammonium
0.05%

Conforms

Fe
0.01%

Conforms

Phosphate
0.1%

Conforms

Loss on drying
≤6.0%1.3%

Heavy metals
0.002%

Conforms

Arsenide
0.0001%

Conforms

Bacterial Endotoxins
0.3EU/mg

Conforms

Microbial Limit
Conforms

Conforms
Assay(on dried basis)≥98.0%98.8%
Conclusion: The results conform with CP2010

my contact infomation is:

Email: cloris_2016@tuskwei.com or

bettytuskwei@yahoo.com

Skype: betty_3451

Website: http://www.tuskwei.net/


Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body

没有评论:

发表评论